Takeda concludes sale of select OTC and non-core assets to Hypera Pharma
This divestment agreement was first announced in March 2020
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Takeda Pharmaceutical Company
Takeda to divest select assets in China to Hasten Biopharmaceutic for $322 mn
The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China